Aprea Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
Mailing Address
3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
Phone
215-948-4119
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$-1.93
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| S-3/A Shelf registration amendment | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
Material Events
8-K
Financial Distress
January 23, 2026
High Impact
- Eprenetapopt Phase 3 trial successfully met its primary goal (complete remission rate) in Myelodysplastic Syndromes (MDS).
- Meeting the primary goal validates the drug's mechanism of action and initial effectiveness, keeping the commercialization pathway open.
Insider Trading
BUY
3 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.